Fc-engineered monoclonal antibodies to reduce off-target liver uptake.

"Declarations Ethics approval and consent to participateAll animal experiments were performed in compliance with the European directive (2010/63/EU) and the INSERM standards for experimental animal studies (agreement E34-172-27). They were approved by the Institut de Recherche en Cancérologie de Montpellier (IRCM/INSERM U1194) and the Languedoc Roussillon region (CEEA LR France No. 36) ethics committees. A statement confirming the study was carried out in compliance with the ARRIVE guidelines. Consent for publicationNot applicable. Competing interestsAuthors have no competing of interest to disclose. Competing interests Authors have no competing of interest to disclose."

"Funding T. Mangeat had a PhD studentship from the Ligue Nationale Contre le Cancer. This work was supported by a grant of Ligue Régionale contre le Cancer de la Lozère; the French National Research Agency under the program Investissements d'Avenir Grant Agreement LabEx MAbImprove (Grant No. ANR‑10‑LABX‑53) and the SIte de Recherche Intégrée sur le Cancer (SIRIC) Montpellier‑Cancer (Grant No. INCa‑DGOS‑Inserm 6045)."